REFERENCES
- Webb W.R., Gatsonis C., Zerhouni E.A., et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178: 705–713
- Hubner K.F., Buonocore E., Singh S.K., Gould H.R., Cotton D.W. Characterization of chest masses by FDG positron emission tomography. Clin. Nucl. Med. 1995; 20: 293–298
- Duhaylongsod F.G., Lowe V.J., Patz E.F., Jr., Vaughn A.L., Coleman R.E., Wolfe W.G. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J. Thorac. Cardiovasc. Surg. 1995; 110: 130–140
- Dewan N.A., Reeb S.D., Gupta N.C., Gobar L.S., Scott W.J. PET–FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995; 108: 441–446
- Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur. J. Nucl. Med. 1996; 23: 1409–1415
- Knight S.B., Delbeke D., Stewart J.R., Sandler M.P. Evaluation of pulmonary lesions with FDG–PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982–988
- Lowe V.J., Duhaylongsod F.G., Patz E.F., et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997; 202: 435–439
- Erasmus J.J., McAdms H.P., Patz E.F., Coleman R.E., Ahuma V., Goodman P.C. Evaluation of primary pulmonary carcinoid tumors using positron emission tomography with 18F-fluorodeoxyglucose. AJR 1998; 170: 1369–1373
- Higashi K., Ueda Y., Seki H., et al. Fluorine-18-FDG PET imaging is negative in bronchioalveolar lung carcinoma. J. Nucl. Med. 1998; 39: 1016–1020
- Delbeke D., Martin W.H., Sandler M.P., Chapman W.C., Wright J.K., Jr., Pinson C.W. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg. 1998; 133: 510–516
- Farber L.A., Benard F., Machtay M., et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999; 109: 970–975
- Montravers F., Grahek D., Kerrou K., et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J. Nucl. Med. 2000; 41: 78–84
- Palmedo H., Bender H., Grunwald F., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur. J. Nucl. Med. 1997; 24: 1138–1145
- Cremerius U., Wildberger J.E., Borchers H., et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?—Results of a study in 50 patients. Urology 1999; 54: 900–904
- Hubner K.F., Buonocore E., Singh S.K., Gould H.R., Cotton D.W. Characterization of chest masses by FDG positron emission tomography. Clin. Nucl. Med. 1995; 20: 293–298
- Duhaylongsod F.G., Lowe V.J., Patz E.F., Jr., Vaughn A.L., Coleman R.E., Wolf W.G. Detection of primary and recurrent lung cancer by means of F-18 fluoro-deoxyglucose positron emission tomography (FDG PET). J. Thorac. Cardiovasc. Surg. 1995; 110: 130–140
- Knight S.B., Delbeke D., Stewart J.R., Sandler M.P. Evaluation of pulmonary lesions with FDG–PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982–988
- Gupta N.C., Maloof J., Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J. Nucl. Med. 1996; 37: 943–948
- Lowe V.J., Duhaylongsod F.G., Patz E.F., et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997; 202: 435–439
- Prauer H.W., Weber W.A., Romer W., Treumann T., Ziegler S.I., Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F] fluorodeoxyglucose in the evaluation of pulmonary nodules. Br. J. Surg. 1998; 85: 1506–1511
- Ber G.M., Gupta N.C., Murray G.F. Positron emission tomography imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J. Thorac. Cardiovasc. Surg. 1999; 117: 719–727
- Halter G., Storck, Guhlmann A., Frank J., Grosse S., Liewald F. FDG positron emission tomography in diagnosis of peripheral pulmonary focal lesions. Thorac. Cardiovasc. Surg. 2000; 48: 97–101